ANI PHARMACEUTICALS INC
ANIPNasdaq
$79.20
↓ -3.3%Jul 17 close · end-of-day
Price
1Y↑ +18.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.7B
Enterprise Value
$1.7B
P/E
20.3
P/S
1.8
P/B
3.0
EV/EBITDA
8.0
PEG
—
FCF Yield
11.2%
Dividend Yield
—
Revenue (TTM)
$923.7M
Net Income (TTM)
$91.8M
Free Cash Flow (TTM)
$191.2M
Gross Margin
—
Operating Margin
13.4%
Net Margin
9.9%
ROE
16.3%
ROIC
17.7%
Debt / Equity
0.5
Net Cash
$5.9M
Return 1Y
+16.4%
Company profile
ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
- CEO
- Nikhil Lalwani
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 600
- Headquarters
- Minnesota
- Website
- anipharmaceuticals.com
Management & directors
- Cook MeredithSR. VP, GENERAL COUNSEL & SEC.
- Carey Stephen P.SVP & CFO
- Gutwerg OriSVP, GENERICS
- Rowland Thomas AndrewSVP, HEAD - ESTABLISHED BRANDS
- Lalwani NikhilPRESIDENT & CEO
- Mutz ChristopherHEAD OF RARE DISEASE
- Davis KristaSVP, CHIEF HR OFFICER
- Gassert ChadSVP - CORP. DEV. & STRATEGY
- Shanmugam MuthusamyHEAD OF R&D, COO-NOVITIUM OPS
Roles derived from SEC Form 4 filings.
Earnings
ANIP Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$237.5M↑ +20.5%
Diluted EPS$1.28↑ +85.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $208.5M | $216.1M | $316.4M | $486.8M | $614.4M | $883.4M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$16.0M | -$39.8M | -$35.3M | $47.0M | $584,000.00 | $111.1M |
| Net income | -$22.5M | -$43.0M | -$48.0M | $19.0M | -$19.0M | $78.0M |
| Diluted EPS | -$1.88 | -$3.40 | -$3.05 | $0.85 | -$1.04 | $3.32 |
| Operating cash flow | $15.3M | $3.3M | -$31.2M | $119.0M | $64.0M | $185.2M |
| Free cash flow | $9.1M | $765,000.00 | -$40.1M | $110.1M | $47.8M | $171.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -7.7% | -18.4% | -11.2% | 9.6% | 0.1% | 12.6% |
| Net margin | -10.8% | -19.9% | -15.2% | 3.9% | -3.1% | 8.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $138.0M | $148.3M | $190.6M | $197.1M | $211.4M | $227.8M | $247.1M | $237.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $5.2M | -$20.5M | -$4.4M | $26.2M | $13.9M | $36.2M | $34.8M | $38.9M |
| Net income | -$2.3M | -$24.2M | -$10.8M | $15.7M | $8.5M | $26.6M | $27.2M | $29.5M |
| Diluted EPS | -$0.14 | -$1.27 | -$0.45 | $0.69 | $0.36 | $1.13 | $1.14 | $1.28 |
| Operating cash flow | $17.4M | $12.5M | $15.9M | $35.0M | $75.8M | $44.1M | $30.4M | $58.4M |
| Free cash flow | $13.0M | $7.7M | $13.5M | $32.5M | $71.8M | $38.0M | $29.1M | $52.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 3.7% | -13.8% | -2.3% | 13.3% | 6.6% | 15.9% | 14.1% | 16.4% |
| Net margin | -1.7% | -16.3% | -5.6% | 8.0% | 4.0% | 11.7% | 11.0% | 12.4% |
Company news
Jul 16, 2026
Jul 13, 2026
- 7d agoANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitisfinance.yahoo.com
- 7d agoANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Runfool.com
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Cook Meredith· SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $81.84 | $40,920.00 | filing |
| 2026-07-02 | CAREY STEPHEN P.· SVP & CFO | Sale | 3,313 | $86.00 | $284,918.00 | filing |
| 2026-07-02 | CAREY STEPHEN P.· SVP & CFO | Option exercise | 3,313 | $49.51 | $164,026.63 | filing |
| 2026-06-29 | CAREY STEPHEN P.· SVP & CFO | Sale | 2,850 | $84.12 | $239,742.00 | filing |
| 2026-06-12 | Cook Meredith· SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $82.03 | $41,015.00 | filing |
| 2026-06-08 | HAUGHEY THOMAS | Sale | 2,000 | $80.88 | $161,760.00 | filing |
| 2026-06-05 | CAREY STEPHEN P.· SVP & CFO | Sale | 3,312 | $80.00 | $264,960.00 | filing |
| 2026-06-05 | CAREY STEPHEN P.· SVP & CFO | Option exercise | 3,312 | $49.51 | $163,977.12 | filing |
| 2026-05-21 | Thoma Jeanne | Award | 4,357 | $0.00 | $0.00 | filing |
| 2026-05-21 | TANNENBAUM RENEE P | Award | 4,357 | $0.00 | $0.00 | filing |
| 2026-05-21 | Pera Antonio R | Award | 4,357 | $0.00 | $0.00 | filing |
| 2026-05-21 | Leonard Matthew J | Award | 4,357 | $0.00 | $0.00 | filing |
| 2026-05-21 | HAUGHEY THOMAS | Award | 4,357 | $0.00 | $0.00 | filing |
| 2026-05-13 | Walsh Patrick D | Sale | 10,000 | $80.63 | $806,300.00 | filing |
| 2026-05-13 | Cook Meredith· SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $78.16 | $39,080.00 | filing |
| 2026-05-12 | Gutwerg Ori· SVP, GENERICS | Sale | 2,772 | $79.50 | $220,374.00 | filing |
| 2026-05-12 | Rowland Thomas Andrew· SVP, HEAD - ESTABLISHED BRANDS | Sale | 459 | $79.21 | $36,357.39 | filing |
| 2026-05-11 | Lalwani Nikhil· PRESIDENT & CEO | Sale | 55,000 | $77.57 | $4.3M | filing |
| 2026-05-11 | Walsh Patrick D | Sale | 3,973 | $80.75 | $320,819.75 | filing |
| 2026-04-13 | Cook Meredith· SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $77.95 | $38,975.00 | filing |
| 2026-03-13 | Mutz Christopher· HEAD OF RARE DISEASE | Sale | 3,162 | $71.64 | $226,525.68 | filing |
| 2026-03-13 | Cook Meredith· SR. VP, GENERAL COUNSEL & SEC. | Sale | 500 | $72.62 | $36,310.00 | filing |
| 2026-03-11 | Rowland Thomas Andrew· SVP, HEAD - ESTABLISHED BRANDS | Sale | 4,772 | $74.91 | $357,470.52 | filing |
| 2026-03-09 | Davis Krista· SVP, CHIEF HR OFFICER | Sale | 5,087 | $74.13 | $377,099.31 | filing |
| 2026-03-09 | Mutz Christopher· HEAD OF RARE DISEASE | Sale | 3,602 | $74.18 | $267,196.36 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.